[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633541":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":65,"collaborators":11,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":11,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":11,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Shandong Suncadia Medicine Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group A: HRS-7535","EXPERIMENTAL",null,[13],"Drug: HRS-7535",{"label":15,"type":16,"description":11,"interventionNames":17},"Treatment group B: Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,24],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","HRS-7535",[9],{"type":21,"name":25,"description":25,"armGroupLabels":26,"otherNames":11},"Placebo",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Pengfei Wang","CONTACT","0518-82342973","pengfei.wang.pw5@hengrui.com",[34,52],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Peking University First Hospital","RECRUITING","Beijing","Beijing Municipality","100034","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49],{"name":50,"role":51,"phone":11,"phoneExt":11,"email":11},"Jianping Li","PRINCIPAL_INVESTIGATOR",{"facility":53,"status":36,"city":54,"state":55,"zip":56,"country":40,"countryCode":41,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"The First Affiliated Hospital of Harbin Medical University","Harbin","Heilongjiang","163711",{"type":43,"coordinates":58},[59,60],126.65,45.75,{"lat":60,"lon":59},[63],{"name":64,"role":51,"phone":11,"phoneExt":11,"email":11},"Yue Li",{"type":66,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100633541","phase-3-phase-iii-study-of-hrs-7535-for-hypertension-with-overweight-or-obesity-100633541",false,"NCT07528027","Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS-7535 for the Treatment of Hypertension in Participants With Obesity or Overweight","Inclusion Criteria:\n\n1. On the day of signing the informed consent form, the age should be between 18 and 70 years old, with no gender restrictions;\n2. When screening or randomizing, the average office blood pressure meets any of the following conditions: ① 140 mmHg ≤ SBP \\\u003C 170 mmHg, and DBP \\\u003C 110 mmHg; ② 90 mmHg ≤ DBP \\\u003C 110 mmHg, and 130 mmHg ≤ SBP \\\u003C 170 mmHg;\n3. Patients with untreated hypertension, or those who have received stable doses of any or all of the following classes of antihypertensive medications within 30 days prior to screening: 1) angiotensin-converting enzyme inhibitors\u002Fangiotensin receptor blockers (ACEI\u002FARB), 2) thiazides and thiazide-like diuretics, 3) calcium channel blockers. Patients who are currently receiving stable doses of beta blockers (such as metoprolol or atenolol) or mineralocorticoid receptor antagonists (such as spironolactone) and intend to continue these treatments at their current doses may be included in this study;\n4. During screening, BMI should be ≥24 kg\u002Fm2;\n\nExclusion Criteria:\n\n1. Having a known secondary cause of hypertension\n2. History of previously diagnosed heart failure with reduced ejection fraction (HFrEF);\n3. Those who have undergone coronary revascularization within the previous 90 days or plan to undergo it during the trial period;\n4. Diagnosed or suspected with type 1 diabetes, special type of diabetes, or secondary diabetes (excluding gestational diabetes);\n5. History of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic\u002Frequiring treatment of gallbladder disease (excluding those who have undergone cholecystectomy but are still eligible for enrollment as determined by the investigator);","ALL","18 Years","70 Years",{"count":78,"type":79},648,"ESTIMATED","INTERVENTIONAL",[82],"PHASE3","The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;",[85],"Hypertension With Overweight or Obesity","2026-06-03",{"date":88,"type":89},"2026-06-05","ACTUAL",{"date":91,"type":89},"2026-05-29",{"date":93,"type":79},"2028-01",{"name":5,"class":6},2]